View Older Stories View More Recent Stories

Jul 21, 2017 07:31AM Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 21, 2017 07:30AM Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 21, 2017 07:30AM Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 10, 2017 09:33AM Sanofi Genzyme and Alnylam (ANLY) Announces Positive phase 2 Results in Hemophilia A and B
Jul 10, 2017 09:32AM Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
Jul 10, 2017 09:31AM Alnylam Pharma (ALNY) & Sanofi (SNY) Genzyme Announce Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran
Jul 10, 2017 09:30AM Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
Jul 10, 2017 09:30AM Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without I
Jul 7, 2017 07:32AM Alnylam Pharma (ALNY), Sanofi (SNY) Initiate Phase 3 Program for Fitusiran for Hemophilia A and B
Jun 27, 2017 05:47AM Sanofi (SNY) & Regeneron (REGN) Granted EU Marketing Approval from Kevzara (sarilumab) in Combination with Methotrexate
Jun 27, 2017 01:00AM Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
Jun 27, 2017 01:00AM Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
Jun 12, 2017 05:53AM Sanofi (SNY) & Regeneron (REGN) Presents Positive Results on Praluent (alirocumab) for Patients with Diabetes & Hypercholesterolemia
Jun 11, 2017 11:02AM Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 11, 2017 11:01AM Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 11, 2017 11:01AM Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 11, 2017 11:00AM Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 5, 2017 06:28AM Regeneron (REGN) & Sanofi (SNY) Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at ASCO Meetings
Jun 4, 2017 10:00AM Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 4, 2017 10:00AM Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2017 05:53PM Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 22, 2017 05:47PM Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 22, 2017 05:46PM Regeneron (REGN), Sanofi (SNY) Announce FDA Approval of Kevzara for RA
May 22, 2017 05:45PM Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 11, 2017 08:30AM Allegra® Allergy Gears Up for Bike to Work Day Across the U.S.
May 2, 2017 08:30AM Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment
May 2, 2017 08:30AM Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment
Apr 28, 2017 05:45AM Sanofi (SNY) & Regeneron (REGN) Report Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by FDA
Apr 28, 2017 01:02AM Sanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA
Apr 28, 2017 01:00AM Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Apr 25, 2017 08:05AM Regeneron (REGN), Sanofi (SNY) Announce FDA Approval of sBLA for Once-Monthly Dosing Option for Praluent
Apr 25, 2017 08:03AM Sanofi (SNY) & Regeneron Pharmaceuticals (REGN) Report FDA Approval of a New Once-Monthly Dosing Option for Praluent® (Alirocumab) Injection
Apr 25, 2017 08:00AM Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
Apr 25, 2017 08:00AM Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
Apr 24, 2017 05:47AM Regeneron (REGN) & Sanofi (SNY) Announce Positive CHMP Opinion on Kevzara® (sarilumab) from European Medicine Agency
Apr 24, 2017 01:01AM Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Apr 24, 2017 01:00AM Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Mar 28, 2017 01:50PM Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval
Mar 28, 2017 11:41AM Regeneron (REGN) and Sanofi (SNY) Announce FDA Approval of DUPIXENT to Treat Moderate-to-Severe Atopic Dermatitis
Mar 28, 2017 11:40AM Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Mar 28, 2017 11:40AM Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Mar 21, 2017 07:43AM Sanofi (SNY) Announces Results of Social Experiment with Xyzal for Allergy Sufferers
Mar 21, 2017 07:30AM Sanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of Symptoms on Allergy Sufferers in the U.S.
Mar 7, 2017 08:05AM Regeneron (REGN), Sanofi (SNY) to Present New Phase 3 Praluent Injection Trial Analyses at ACC
Mar 7, 2017 08:00AM Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
Mar 4, 2017 10:30AM Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis
Feb 27, 2017 08:35AM Sanofi (SNY) and Regeneron (REGN) to Present New Data on Dupixent for Moderate-to-Severe Atopic Dermatitis
Feb 27, 2017 08:30AM Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
Feb 27, 2017 08:30AM Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
Feb 9, 2017 09:24AM Pre-Open Movers 02/09: (OSUR) (ACOR) (PAYC) Higher; (TWTR) (OII) (QLYS) Lower (more...)
View More Recent Stories View Older Stories